BOSTON—Barbara Weber, the Chief Executive Officer of Tango Therapeutics, Inc. (NASDAQ:TNGX), a $350 million market cap biotech company, recently sold a portion of her holdings in the company.
The FDA will allow two biotechnology companies to run clinical trials: United Therapeutics and eGenesis. United Therapeutics ...
The search for new tuberculosis drug targets under traditional laboratory methods has historically proven to be arduous and ...
AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...
Hosted on MSN1d
GAT-B 2025: Registration for the GAT-B entrance exam starts, know in which courses you get admission through this..National Testing Agency (NTA) has started registration for Graduate Aptitude Test-Biotechnology (GAT-B) 2025. For this, one ...
Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...
The integration of AgIdea will enable SynTech Research Group to expand its portfolio of services in Seeds and Traits and ...
Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners Acquisition of biologics Contract ...
Amid the federal funding uncertainty for health and sciences, local life science leaders say this could be a moment for industry partners, investors and others to step up and support the sector.
The new sorghum varieties provide a climate-smart alternative grain for food science, breweries and dairy farmers ...
Jan. 31, the CDC's chief science officer sent an internal email that informed the agency’s division heads that all papers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback